Abstract
August 16, 2020
Risk-cost-benefit analysis requires the enumeration of decision alternatives, their associated outcomes, and the quantification of uncertainty. Public and private decision-making surrounding the COVID-19 pandemic must contend with uncertainty about the probability of infection during activities involving groups of people, in order to decide whether that activity is worth undertaking. We propose a deterministic linear model of SARS-CoV-2 infection probability that can produce estimates of relative risk for diverse activities, so long as those activities meet a list of assumptions, including that they do not last longer than one day. We show how the model can be used to inform decisions facing governments and industry, such as opening stadiums or flying on airplanes. We prove that the model is a good approximation of a more refined model in which we assume infections come from a series of independent risks. The linearity assumption makes interpreting and using the model straightforward, and we argue that it does so without significantly diminishing the reliability of the model.
Competing Interest Statement
J.E.M., B.A.D. and M.T.M. received funding as consultants for Delaware North, a company that may be affected by the research reported in the paper.
Funding Statement
JEM was partially supported by National Institutes of Health Grant R01 AG052550-01A1 and National Science Foundation Grant DMS 1565243 BDD was partially supported by the Riksbankens Jubileumsfond (Swedish Foundation for the Social Sciences and Humanities) program on Science and Proven Experience JEM, BAD and MTM received funding from Delaware North
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Data Availability
No external data
